Get started
Blueprint Medicines CorporationBlueprint Medicines CorporationBlueprint Medicines Corporation

Blueprint Medicines Corporation

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

BPMC chart


Full chart

BPMC upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.17 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.02 USD
Net income (FY)
‪−67.09 M‬ USD
Revenue (FY)
‪508.82 M‬ USD
Shares float
‪62.65 M‬
Beta (1Y)
1.29

Employees


Employees (FY)
649
Change (1Y)
−6 −0.92%
Revenue / Employee (1Y)
‪784.01 K‬ USD
Net income / Employee (1Y)
‪−103.37 K‬ USD

About Blueprint Medicines Corporation


Sector
Health Technology
Industry
Biotechnology
CEO
Kathryn Haviland
Website
blueprintmedicines.com
Headquarters
Cambridge
Founded
2008
FIGI
BBG001MC8YF7
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BPMC news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as BPMC.

Frequently Asked Questions


The current price of BPMC is 82.53 USD — it has increased by 2.13% in the past 24 hours. Watch Blueprint Medicines Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Blueprint Medicines Corporation stocks are traded under the ticker BPMC.
BPMC stock has risen by 4.51% compared to the previous week, the month change is a −8.71% fall, over the last year Blueprint Medicines Corporation has showed a −10.87% decrease.
We've gathered analysts' opinions on Blueprint Medicines Corporation future price: according to them, BPMC price has a max estimate of 167.00 USD and a min estimate of 83.00 USD. Watch BPMC chart and read a more detailed Blueprint Medicines Corporation stock forecast: see what analysts think of Blueprint Medicines Corporation and suggest that you do with its stocks.
BPMC reached its all-time high on Dec 24, 2020 with the price of 125.61 USD, and its all-time low was 13.04 USD and was reached on Feb 8, 2016. View more price dynamics on BPMC chart.
See other stocks reaching their highest and lowest prices.
BPMC stock is 4.49% volatile and has beta coefficient of 1.29. Track Blueprint Medicines Corporation stock price on the chart and check out the list of the most volatile stocks — is Blueprint Medicines Corporation there?
Today Blueprint Medicines Corporation has the market capitalization of ‪5.27 B‬, it has decreased by −6.68% over the last week.
Yes, you can track Blueprint Medicines Corporation financials in yearly and quarterly reports right on TradingView.
Blueprint Medicines Corporation is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
BPMC earnings for the last quarter are −0.79 USD per share, whereas the estimation was −0.70 USD resulting in a −12.23% surprise. The estimated earnings for the next quarter are −0.51 USD per share. See more details about Blueprint Medicines Corporation earnings.
Blueprint Medicines Corporation revenue for the last quarter amounts to ‪146.37 M‬ USD, despite the estimated figure of ‪145.91 M‬ USD. In the next quarter, revenue is expected to reach ‪156.56 M‬ USD.
BPMC net income for the last quarter is ‪−49.96 M‬ USD, while the quarter before that showed ‪−56.28 M‬ USD of net income which accounts for 11.23% change. Track more Blueprint Medicines Corporation financial stats to get the full picture.
No, BPMC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 649 employees. See our rating of the largest employees — is Blueprint Medicines Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Blueprint Medicines Corporation EBITDA is ‪−195.75 M‬ USD, and current EBITDA margin is −38.47%. See more stats in Blueprint Medicines Corporation financial statements.
Like other stocks, BPMC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Blueprint Medicines Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Blueprint Medicines Corporation technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Blueprint Medicines Corporation stock shows the sell signal. See more of Blueprint Medicines Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.